AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd (ASTRAZEN) last reported results for the quarter ended Jun 2026, with sales of ₹683 crore and net profit of ₹38 crore. The next scheduled event is a corporate event on 10 Feb 2027. The stock last traded at ₹5,837, a market capitalisation of ₹14,632 crore, on a P/E of 84.3. Over the past 52 weeks the stock has ranged between ₹5,640 and ₹9,850. Figures are as of 9 Oct 2026 and are not real time.
AstraZeneca Pharma India Ltd share price and key metrics
- Current price
- ₹5,837
- Market cap
- ₹14,632 cr
- Stock P/E
- 84.3
- Book value
- ₹349
- ROE
- 23.3%
- ROCE
- 29.3%
- Dividend yield
- 0.62%
- 52w high / low
- 9850/5640
Metrics as of 9 Oct 2026. Not real time.
Track AstraZeneca Pharma India Ltd
Cruxal reads every AstraZeneca Pharma India Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
AstraZeneca Pharma India Ltd growth and returns
- 10 Years
- 15%
- 5 Years
- 23%
- 3 Years
- 31%
- TTM
- 31%
- 10 Years
- 43%
- 5 Years
- 16%
- 3 Years
- 15%
- TTM
- -18%
- 10 Years
- 20%
- 5 Years
- 13%
- 3 Years
- 7%
- 1 Year
- -37%
- 10 Years
- 21%
- 5 Years
- 22%
- 3 Years
- 23%
- Last Year
- 23%
AstraZeneca Pharma India Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹683 cr, up 29.8% from ₹526 cr a year earlier. Net profit was ₹38 cr, down 32.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 408 | 440 | 480 | 526 | 559 | 612 | 579 | 683 |
| Expenses | 355 | 363 | 394 | 445 | 484 | 567 | 518 | 634 |
| Operating profit | 53 | 77 | 86 | 81 | 75 | 45 | 61 | 49 |
| OPM % | 13% | 17% | 18% | 15% | 13% | 7% | 11% | 7% |
| Other income | 8 | -26 | 10 | 11 | 1 | 7 | 5 | 9 |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 9 | 9 | 18 | 17 | 3 | 4 | 6 | 5 |
| Profit before tax | 51 | 42 | 78 | 75 | 73 | 47 | 58 | 51 |
| Tax % | 25% | 27% | 26% | 25% | 26% | 30% | 23% | 25% |
| Net profit | 38 | 31 | 58 | 56 | 54 | 33 | 45 | 38 |
| EPS (₹) | 15.37 | 12.34 | 23.30 | 22.33 | 21.69 | 13.04 | 17.95 | 15.17 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
AstraZeneca Pharma India Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 544 | 571 | 728 | 832 | 814 | 806 | 1,003 | 1,296 | 1,716 | 2,276 | 2,432 |
| Operating profit | 37 | 46 | 71 | 121 | 135 | 86 | 165 | 184 | 254 | 262 | 230 |
| OPM % | 7% | 8% | 10% | 15% | 17% | 11% | 16% | 14% | 15% | 12% | 9% |
| Net profit | 20 | 26 | 54 | 72 | 93 | 62 | 99 | 162 | 116 | 188 | 170 |
| EPS (₹) | 8.02 | 10.36 | 21.78 | 28.88 | 37.32 | 24.64 | 39.72 | 64.60 | 46.30 | 75.01 | 67.85 |
TTM is the trailing twelve months to the most recent quarter.
AstraZeneca Pharma India Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 218 | 242 | 296 | 359 | 451 | 506 | 584 | 707 | 765 | 868 |
| Borrowings | 0 | 0 | 0 | 12 | 12 | 9 | 7 | 5 | 36 | 111 |
| Other liabilities | 193 | 214 | 261 | 330 | 306 | 337 | 389 | 362 | 712 | 1,006 |
| Total liabilities | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 | 1,989 |
| Fixed assets | 87 | 75 | 75 | 72 | 81 | 74 | 69 | 67 | 64 | 117 |
| CWIP | 5 | 4 | 7 | 24 | 4 | 2 | 1 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 324 | 382 | 480 | 611 | 690 | 780 | 915 | 1,011 | 1,454 | 1,872 |
| Total assets | 415 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 | 1,989 |
As reported by the company. Total assets equal total liabilities by construction.
AstraZeneca Pharma India Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 38 | 9 | 55 | 87 | 105 | 101 | 58 | 28 | 65 | -15 |
| Cash from investing | 0 | -9 | 4 | -171 | 173 | 5 | 18 | 22 | 31 | 19 |
| Cash from financing | 0 | 0 | 0 | -6 | -9 | -9 | -24 | -44 | -66 | -92 |
| Net cash flow | 38 | -1 | 59 | -90 | 269 | 96 | 52 | 5 | 31 | -88 |
| Free cash flow | 33 | 3 | 37 | 74 | 99 | 94 | 53 | 18 | 64 | -18 |
| CFO / operating profit | 133% | 28% | 126% | 100% | 101% | 146% | 60% | 46% | 51% | 26% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
AstraZeneca Pharma India Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 15% | 19% | 27% | 34% | 30% | 16% | 31% | 31% | 33% | 29% |
| Debtor days | 29 | 35 | 40 | 37 | 38 | 39 | 39 | 43 | 39 | 34 |
| Inventory days | 121 | 229 | 186 | 197 | 198 | 164 | 193 | 140 | 208 | 272 |
| Days payable | 184 | 257 | 266 | 251 | 221 | 223 | 231 | 121 | 173 | 207 |
| Cash conversion cycle | -34 | 7 | -39 | -17 | 15 | -20 | 1 | 62 | 74 | 99 |
| Working capital days | -36 | -8 | -14 | -16 | -17 | -34 | -18 | 20 | 22 | 50 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
AstraZeneca Pharma India Ltd shareholding pattern
Promoters held 75.00% at Jun 2026, broadly unchanged since Jun 2025. FIIs 2.68% and DIIs 6.08%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| FIIs | 2.90% | 2.92% | 2.89% | 3.03% | 2.74% | 2.71% | 2.78% | 2.68% |
| DIIs | 5.08% | 5.21% | 4.65% | 4.55% | 5.26% | 5.55% | 5.79% | 6.08% |
| Public | 17.02% | 16.85% | 17.45% | 17.41% | 17.00% | 16.73% | 16.42% | 16.24% |
| No. of shareholders | 27,615 | 27,322 | 32,466 | 34,378 | 32,914 | 31,551 | 29,007 | 29,338 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming AstraZeneca Pharma India Ltd events
The next scheduled event is a corporate event on 10 Feb 2027.
- Corporate eventHigh Court hearing regarding stay of NPPA demand notice for alleged overcharging
See the full results calendar for every Indian company reporting in the next 30 days.
AstraZeneca Pharma India Ltd corporate filings
- AstraZeneca Pharma India Limited receives minor regulatory penalty from ROC for procedural filing delayCompany Updatelow impact
Cruxal's analysis: AstraZeneca Pharma India Limited has been issued a penalty order by the Registrar of…
Read the full analysis - Please find the enclosed intimation of the Company as per the captioned subject for your reference.Insider Trading / SASTlow impact
- AstraZeneca Pharma India Limited announces resignation of Director – Medical AffairsCompany Updatelow impact
Cruxal's analysis: AstraZeneca Pharma India Limited has formally notified the stock exchanges regarding the…
Read the full analysis - AstraZeneca Pharma India Ltd discloses ESG rating under SEBI Regulation 30Company Updatelow impact
Cruxal's analysis: AstraZeneca Pharma India Ltd has submitted a disclosure regarding its ESG rating in…
Read the full analysis - AstraZeneca Pharma India secures High Court stay on NPPA demand notice regarding Betaloc-50 pricingCompany Updatemedium impact
Cruxal's analysis: AstraZeneca Pharma India Limited has received a stay order from the Hon'ble High Court of…
Read the full analysis - AstraZeneca Pharma India Ltd discloses ESG rating updateCompany Updatelow impact
Cruxal's analysis: AstraZeneca Pharma India Ltd has submitted a disclosure regarding its ESG rating in…
Read the full analysis - AstraZeneca Pharma India Ltd announces intimation for Analyst/Investor meetCompany Updatelow impact
Cruxal's analysis: AstraZeneca Pharma India Ltd has filed a routine intimation regarding an upcoming analyst…
Read the full analysis - AstraZeneca Pharma India Ltd announces scheduled analyst/investor meetCompany Updatelow impact
Cruxal's analysis: AstraZeneca Pharma India Ltd has filed an intimation regarding an upcoming…
Read the full analysis - AstraZeneca Pharma India Limited concludes 47th AGM; shareholders approve dividend of INR 36 per shareAGM/EGMlow impact
Cruxal's analysis: AstraZeneca Pharma India Limited has successfully concluded its 47th Annual General…
Read the full analysis - AstraZeneca Pharma India Ltd releases routine press statementCompany Updatelow impact
Cruxal's analysis: AstraZeneca Pharma India Ltd has filed a press release under Regulation 30 of the SEBI…
Read the full analysis - AstraZeneca Pharma India Limited concludes 47th AGM; approves dividend of INR 36 per shareAGM/EGMlow impact
Cruxal's analysis: AstraZeneca Pharma India Limited has successfully concluded its 47th Annual General…
Read the full analysis - AstraZeneca Pharma India Reports Strong Q1 FY27 Results with 30% Revenue Growth and Key Regulatory MilestonesResulthigh impact
Cruxal's analysis: AstraZeneca Pharma India Limited delivered a robust performance for the quarter ended…
Read the full analysis - AstraZeneca Pharma India Ltd files routine regulatory intimation under SEBI Regulation 30Company Updatelow impact
Cruxal's analysis: AstraZeneca Pharma India Ltd has submitted a routine disclosure under Regulation 30 of…
Read the full analysis - AstraZeneca Pharma India to Hold Board Meeting on August 10, 2026, for Q1 FY27 Un-audited Financial ResultsBoard Meetinglow impact
Cruxal's analysis: AstraZeneca Pharma India Limited has announced that its Board of Directors will convene…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.